Oct212021UncategorizedCategory: UncategorizedBy Charlotte Maddalena21 October 2021 Author: Charlotte Maddalena Post navigationPreviousPrevious post:Jeremy Bastid and Hugues Bienayme will participate to the SIOPEN annual meeting to be held 6-8 October in BarcelonaNextNext post:ORPHELIA Pharma and K.S. KIM sign a license agreement for the distribution of Kigabeq® in the territory of the Russian federationRelated PostsSix new projects supported by our Foundation18 March 2024Four houses for the FAOMA call for projects18 March 2024ORPHELIA Pharma announces the publication of two scientific articles on KIZFIZO, the first pediatric drinkable formulation of temozolomide for the treatment of refractory or relapsed neuroblastoma9 January 2024Seven new projects supported by our Foundation8 January 2024Newsletter December 202318 December 2023Orphelia Pharma secures US patent covering KIZFIZO®, first drinkable formulation of temozolomide29 November 2023
ORPHELIA Pharma announces the publication of two scientific articles on KIZFIZO, the first pediatric drinkable formulation of temozolomide for the treatment of refractory or relapsed neuroblastoma9 January 2024
Orphelia Pharma secures US patent covering KIZFIZO®, first drinkable formulation of temozolomide29 November 2023